GSK files NDA resubmission for tebipenem HBr; Spero to receive $25M milestone in Q1 2026

Spero Therapeutics, Inc.

GSK resubmitted NDA to FDA for oral carbapenem tebipenem HBr for cUTI/pyelonephritis.
Resubmission triggers $25 million milestone payment to Spero, expected Q1 2026.
Spero's tebipenem HBr is investigational; approval not guaranteed.

item 8.01 item 9.01

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-325821

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.